Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 1: | Line 1: | ||
== Summary == | == Summary == | ||
Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening | Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening tumour defence mechanisms. Oncolytics Biotech aims to use immunotherapeutics - a branch of biological therapies that use synthetic substances to activate the immune system for stronger responses. This approach proposes many new treatments that will support the immune system in a more powerful fight against cancer. The company's lead product is Pelareorep, simply put, Pelareorep is an oncolytic virus that causes tumour cells to burst and activates multiple immune system entities. | ||
Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | ||
== Introduction: == | |||
== | |||
=== | === Operation: Cutting-Edge Research and Development in Oncolytic Virotherapy === | ||
At the forefront of the battle against cancer, Oncolytics Biotech Inc. operates on the cutting edge of oncolytic virotherapy research and development. The company's operations revolve around harnessing the power of viruses to selectively target and destroy cancer cells while sparing healthy tissues. Through a meticulous approach, Oncolytics Biotech's team of scientists, physicians, and industry experts works tirelessly to develop innovative oncolytic viruses that exploit the vulnerabilities of cancer cells. | At the forefront of the battle against cancer, Oncolytics Biotech Inc. operates on the cutting edge of oncolytic virotherapy research and development. The company's operations revolve around harnessing the power of viruses to selectively target and destroy cancer cells while sparing healthy tissues. Through a meticulous approach, Oncolytics Biotech's team of scientists, physicians, and industry experts works tirelessly to develop innovative oncolytic viruses that exploit the vulnerabilities of cancer cells. | ||
=== | === Mission: Transforming Lives by Redefining Cancer Treatment === | ||
Oncolytics Biotech Inc. is driven by a powerful mission: to transform the lives of cancer patients by redefining the way cancer is treated. With a deep commitment to advancing oncolytic virotherapy, the company aims to provide more effective and personalized treatment options that maximize therapeutic outcomes. By leveraging the body's own immune system and developing targeted therapies, Oncolytics Biotech seeks to revolutionize the field of oncology and improve patient outcomes worldwide. | Oncolytics Biotech Inc. is driven by a powerful mission: to transform the lives of cancer patients by redefining the way cancer is treated. With a deep commitment to advancing oncolytic virotherapy, the company aims to provide more effective and personalized treatment options that maximize therapeutic outcomes. By leveraging the body's own immune system and developing targeted therapies, Oncolytics Biotech seeks to revolutionize the field of oncology and improve patient outcomes worldwide. | ||
Please note that the above paragraphs are generated based on the information available on the official website of Oncolytics Biotech Inc. as of my knowledge cutoff in September 2021. For the most up-to-date and accurate information, please refer to the company's official communications and documents. | |||
== Market == | == Market == | ||
Line 102: | Line 21: | ||
The total addressable market is used to define the revenue opportunity available for a product or service. TAM helps prioritise business opportunities by serving as a quick metric of a given opportunity's underlying potential. | The total addressable market is used to define the revenue opportunity available for a product or service. TAM helps prioritise business opportunities by serving as a quick metric of a given opportunity's underlying potential. | ||
For Oncolytics Biotechnology , we define the TAM as the global biotechnology market. | For Oncolytics Biotechnology , we define the TAM as the global biotechnology market. It is estimated that the size of this market, based on revenue figures is USD 378 billion . <ref name=":0" /> | ||
=== Serviceable Available Market (SAM): === | === Serviceable Available Market (SAM): === | ||
Here, the serviceable available market is defined as the global oncolytics cancer virus therapy market. Taking several factors into consideration, the SAM for Oncolytics Biotech is | Here, the serviceable available market is defined as the global oncolytics cancer virus therapy market. Taking several factors into consideration, the SAM for Oncolytics Biotech is estimated to be USD 22.86 million in 2023. <ref>https://www.futuremarketinsights.com/reports/oncolytic-virus-cancer-therapy-market</ref> | ||
== Executive Team and Board of Directors: == | == Executive Team and Board of Directors: == | ||
Line 115: | Line 34: | ||
=== '''Management Team at Oncolytics Biotech.:''' === | === '''Management Team at Oncolytics Biotech.:''' === | ||
'''Matt Coffey, PhD, MBA''' is the '''Chief Executive Officer and President''' of Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncolytics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. | '''Matt Coffey, PhD, MBA''' is the '''Chief Executive Officer and President''' of Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncolytics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. | ||
[[File:Screenshot 2023-07-22 at 11.00.53.png|thumb|188x188px|Kirk Look - CFO ]] | |||
'''Kirk Look''' is the '''Chief Financial Officer''' of Oncolytics and is a highly experienced chartered accountant. Before joining the company in 2003 Look was the manager of Audit and Assurance services in the prestigious accounting firm Ernst & Young in Canada. | '''Kirk Look''' is the '''Chief Financial Officer''' of Oncolytics and is a highly experienced chartered accountant. Before joining the company in 2003 Look was the manager of Audit and Assurance services in the prestigious accounting firm Ernst & Young in Canada. | ||
[[File:Screenshot 2023-07-22 at 11.07.29.png|thumb|179x179px|Allison Hagerman - Vice President ]] | [[File:Screenshot 2023-07-22 at 11.07.29.png|thumb|179x179px|Allison Hagerman - Vice President ]] | ||
'''Allison Hagerman''' is the '''Vice President of Product Development''' at Oncolytics. Ms. Hagerman is a biotechnology professional engineer and has been Director of Manufacturing and Engineering and Project Manager in Oncolytics. During this time she led the team to for the performance qualification of Pelareorep drug substance. | |||
'''Allison Hagerman''' is the '''Vice President of Product Development''' at Oncolytics. Ms. Hagerman is a biotechnology professional engineer and has been Director of Manufacturing and Engineering and Project Manager in Oncolytics. During this time she led the team to for the performance qualification of Pelareorep drug substance. | |||
[[File:Screenshot 2023-07-22 at 11.07.38.png|thumb|171x171px|Andrew de Guttadauro - Global head of Business Development, President ]] | [[File:Screenshot 2023-07-22 at 11.07.38.png|thumb|171x171px|Andrew de Guttadauro - Global head of Business Development, President ]] | ||
'''Andrew de Guttadauro''' is the '''President and Global Head of Business Development''' at Oncolytics Biotech. Mr. Guttadauro has held executive and senior-level positions at leading pharmaceutical and biotechnology companies. | '''Andrew de Guttadauro''' is the '''President and Global Head of Business Development''' at Oncolytics Biotech. Mr. Guttadauro has held executive and senior-level positions at leading pharmaceutical and biotechnology companies. | ||
'''Thomas C. Heineman, MD, PhD''' is the '''Chief Medical Officer''' of Oncolytics. He completed his PhD at the University of Chigaco in Virology. Prior to his position in Oncolytics Dr Heineman worked in various roles which were Head of clinical development at Denovo, Vice President, Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics, Senior Director of Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. | '''Thomas C. Heineman, MD, PhD''' is the '''Chief Medical Officer''' of Oncolytics. He completed his PhD at the University of Chigaco in Virology. Prior to his position in Oncolytics Dr Heineman worked in various roles which were Head of clinical development at Denovo, Vice President, Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics, Senior Director of Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. | ||
Line 132: | Line 59: | ||
=== '''Board of Directors at Oncolytics Biotech.:''' === | === '''Board of Directors at Oncolytics Biotech.:''' === | ||
'''Matt Coffey, PhD, MBA''' is a '''Director''' in Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. | '''Matt Coffey, PhD, MBA''' is a '''Director''' in Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. | ||
'''Wayne Pisano''' is a '''Director''' at Oncolytics and has had a very successful career and been recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He has served a plethora of roles including: President and CEO of VaxInnate (a privately held biotech company), member of Immunovaccine's Board in October 2011 and lastly he was the former President and CEO of Sanofi Pasteur (one of the largest vaccine companies in the world). | '''Wayne Pisano''' is a '''Director''' at Oncolytics and has had a very successful career and been recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He has served a plethora of roles including: President and CEO of VaxInnate (a privately held biotech company), member of Immunovaccine's Board in October 2011 and lastly he was the former President and CEO of Sanofi Pasteur (one of the largest vaccine companies in the world). | ||
'''Jonathan Rigby''' is a '''Director''' at Oncolytics. He is currently the Group Chief Executive Officer of Revolo Biotherapeutics, where he is focused on the development of therapies for autoimmune and allergic diseases. Other than this he has lots of experience in the biotech industry including CEO of SteadyMed Ltd, Co-founding Zogenix, Inc. (a CNS-focused specialty pharmaceutical company), being a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and lastly the Chairman of BIOS (a Nasdaq-listed biotech acquisition company). | '''Jonathan Rigby''' is a '''Director''' at Oncolytics. He is currently the Group Chief Executive Officer of Revolo Biotherapeutics, where he is focused on the development of therapies for autoimmune and allergic diseases. Other than this he has lots of experience in the biotech industry including CEO of SteadyMed Ltd, Co-founding Zogenix, Inc. (a CNS-focused specialty pharmaceutical company), being a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and lastly the Chairman of BIOS (a Nasdaq-listed biotech acquisition company). | ||
'''Deborah M. Brown, MBA''' is a '''Director''' at Oncolytics. Ms. Brown has many achievements including being a current Managing Partner at Accelera (a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe) Canada. She has previously been Executive Vice President of Neuroimmunology and President and Managing Director of the company's Canadian operations at EMD Serono. Ms. Brown has also been Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada), Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. | '''Deborah M. Brown, MBA''' is a '''Director''' at Oncolytics. Ms. Brown has many achievements including being a current Managing Partner at Accelera (a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe) Canada. She has previously been Executive Vice President of Neuroimmunology and President and Managing Director of the company's Canadian operations at EMD Serono. Ms. Brown has also been Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada), Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. | ||
'''Bernd R. Seizinger, MD, PhD''' is a '''Director''' at Oncolytics. Dr. Bernd., currently serves as board member in numerous public and private biotech companies including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. In previous roles he was simultaneously President & CEO of GPC Biotech (VP Oncology Drug Discovery) while also serving as VP Corporate and Academic Alliances at Bristol-Myers Squibb, and as Executive VP and CSO of Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University. | '''Bernd R. Seizinger, MD, PhD''' is a '''Director''' at Oncolytics. Dr. Bernd., currently serves as board member in numerous public and private biotech companies including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. In previous roles he was simultaneously President & CEO of GPC Biotech (VP Oncology Drug Discovery) while also serving as VP Corporate and Academic Alliances at Bristol-Myers Squibb, and as Executive VP and CSO of Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University. | ||
''' | '''James T. Parsons''' is a '''Director''' at Oncolytics. His executive experience includes, currently, being Chief Financial Officer of Trillium Therapeutics Inc. Previosuly he has been president of Empar Management, Vice President of Finance at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President of Finance and Administration at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has also been a Director and the Chair of the Audit Committees of Sernova Corp. and DiaMedica Therapeutics Inc. | ||
'''Angela Holtham, MBA,''' is a '''Director''' at Oncolytics. She is currently the Senior Vice President and Chief Financial Officer of Canadian subsidiary of Nabisco Inc. She has also been the Vice President, Finance and Chief Financial Officer in the Ontario-based Hospital for Sick Children. | |||
== | == Product == | ||
Oncolytics’ core product is Pelareorep which targets cancerous cells. Cancer cells (tumour cells) are unique in comparison to other cells in the body as they can rapidly multiply due to a cell signalling pathway they carry out called the RAS-activated pathway. Pelareorep can target this pathway as it is a reovirus. Reoviruses are a group of RNA double stranded viruses which have the ability to recognise unique glycans on cancerous cells via sigma-1 protein to allow immune system enhancement. The Ras-activated pathway which is required for Pelareorep to function is only present in cancerous cells, this includes some of the most common cancers such as lung and breast cancer. | |||
Pelareorep is injected intravenously, once it interacts with a Ras-activated cancer cells it rapidly multiplies which causes: | |||
* Release of cytokines (innate) | |||
* Activation of Natural Killer cells (innate) | |||
* Dendritic cell activation (innate) | |||
* T cell education and activation (adaptive) | |||
* Tumour cell lysis | |||
* Activation of the interferon-gamma (IFN-γ) signalling pathway | |||
After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells, until all cancerous cells have been defeated. Pelareorep has shown a successful immune response without immune over-activation as clinical research has shown a balanced Treg : (CD8 +) T cell ratio. | |||
Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have moved to Phase III clinical trials, as they are showing promising results. | |||
Pelareorep is manufactured at a commercial scale under a commercial supply agreement with MilliporeSigma (formerly Sigma-Aldrich). At the moment, Pelareorep is mainly supplied within Canada and the US, however the company is looking to expand with 17 pending patent applications currently. | |||
Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at $18 for a supply of 5 milliliters. | |||
== Major Stakeholders in Oncolytics Biotech:- == | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
Line 183: | Line 136: | ||
|} | |} | ||
== Risks | == Risks == | ||
As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high. | As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high. | ||
Line 207: | Line 160: | ||
* Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made__INDEX__ | * Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made__INDEX__ | ||
== Relative Valuation== | == Relative Valuation== | ||
Line 315: | Line 172: | ||
! colspan="2" |Valuation (x) | ! colspan="2" |Valuation (x) | ||
|- | |- | ||
|Company | |||
|Ticker | |||
| Price | |||
|Shares Out | |||
|Market Cap | |||
| TEV | |||
|Revenue | |||
|EBITDA | |||
| EBIT | |||
|Net Income | |||
|Assets | |||
|Liabilities | |||
|Book Value | |||
|R&D Exp. | |||
| P/B | |||
| EV/R&D | |||
|- | |- | ||
|<u>Oncolytics Biotech Inc.</u> | |<u>Oncolytics Biotech Inc.</u> | ||
Line 364: | Line 221: | ||
|8148 | |8148 | ||
| -12,25x | | -12,25x | ||
|0. | |0.99X | ||
|- | |- | ||
|Faron Pharmaceuticals | |Faron Pharmaceuticals | ||
Line 417: | Line 274: | ||
|0.08x | |0.08x | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|} | |} | ||
Below presents brief introduction to Oncolytic's peers; note by nature of the drug discovery industry, each company's focus and addressable market can vary. | Below presents brief introduction to Oncolytic's peers; note by nature of the drug discovery industry, each company's focus and addressable market can vary. | ||
Line 469: | Line 309: | ||
|Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to support the development of next-generation CAR T-cell candidates in solid tumors and hematological malignancies. | |Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to support the development of next-generation CAR T-cell candidates in solid tumors and hematological malignancies. | ||
|- | |- | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
|} | |} | ||
== References == | == Summary == | ||
Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening tumour defence mechanisms. Oncolytics Biotech aims to use immunotherapeutics - a branch of biological therapies that use synthetic substances to activate the immune system for stronger responses. This approach proposes many new treatments that will support the immune system in a more powerful fight against cancer. The company's lead product is Pelareorep, simply put, Pelareorep is an oncolytic virus that causes tumour cells to burst and activates multiple immune system entities. | |||
Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | |||
== References<ref>https://pubmed.ncbi.nlm.nih.gov/25693885/</ref> == | |||
<references /> | <references /> |